Health Trials

About this trial

This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.

Eligibility criteria

Qualifiers

HCT recipients (Auto or Allograft)

SOS/VOD as defined by Cairo/Cooke Diagnostic criteria (1) (Table 3) with either renal and/or pulmonary dysfunction as defined by Cairo/Cooke Grading criteria (1) (Appendix I).

Patients with SOS/VOD failing to obtain a complete response (CR) defined by Grade I or less by Cairo/Cooke Grading criteria (1) (Appendix I). This would therefore include patients with stable disease after at least 14 days of defibrotide or partial response after at least 21 days of defibrotide (25mg/kg/day).

Progressive disease defined by progression of at least one grade or more from diagnostic grade as defined by Cairo/Cooke Grading criteria (1) (Appendix I) following at least 7 days of defibrotide (25mg/kg/day).

Disqualifiers

Patients who did not receive HCT.

Concomitant systemic anticoagulation (excluding central venous line management, fibrinolytic instillation for central venous line occlusion, management of intermittent dialysis or ultrafiltration of CVVH).

Active bleeding and/or hemorrhage of at least grade 2 and above.

History of development of Grade III/IV anaphylaxis probably or directly secondary to defibrotide.

Trial design

Treatments tested in this trial

  • Defibrotide

Treatment groups

20 Participants
are divided into 1 treatment group

Locations

1
New York Medical College10595, VallhalaNew York, United States

Sponsors and collaborators

New York Medical College

Lead sponsor

Source ClinicalTrials.gov